Dova Pharmaceuticals (DOVA) plans to raise $66 million in an initial public offering on Wednesday, June 28th, IPO Scoop reports. The company will issue 4,100,000 shares at $15.00-$17.00 per share.

Dova Pharmaceuticals has a market cap of $394.2 million.

J.P. Morgan, Jefferies and Leerink Partners served as the underwriters for the IPO.

Dova Pharmaceuticals provided the following description of their company for its IPO: “We are a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Our drug candidate, avatrombopag, which we acquired from Eisai, Inc., or Eisai, in March 2016, is an orally administered thrombopoietin receptor agonist, or TPO-RA, that we are developing for the treatment of thrombocytopenia. “.

Dova Pharmaceuticals was founded in 2016 and has 7 employees. The company is located at 2530 Meridian Pkwy, Suite 300, Durham, NC, 27713, US and can be reached via phone at (919) 806-4487 or on the web at http://www.dova.com.

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.